Photo from wikipedia
A clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma (HCC). In this study, we evaluated this therapeutic combination in a… Click to show full abstract
A clinical trial (IMbrave150) indicated the efficacy and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma (HCC). In this study, we evaluated this therapeutic combination in a real‐world setting, with a focus on patients who did not meet the IMbrave150 eligibility criteria.
Keywords:
hepatocellular carcinoma;
unresectable hepatocellular;
atezolizumab plus;
patients meet;
safety atezolizumab;
plus bevacizumab
Journal Title: Hepatology Research
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hepatology Research
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!